Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 12:12 am EST
Share
Ilsung Pharmaceuticals Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 1,045.25 million compared to KRW 916.12 million a year ago. Net income was KRW 3,283.48 million compared to KRW 751.74 million a year ago. Basic earnings per share from continuing operations was KRW 442.8 compared to KRW 98 a year ago. Basic earnings per share was KRW 442.8 compared to KRW 98 a year ago.
For the nine months, sales was KRW 3,490.91 million compared to KRW 2,782.78 million a year ago. Net income was KRW 103,718.98 million compared to net loss of KRW 4,740.25 million a year ago. Basic earnings per share from continuing operations was KRW 13,870.4 compared to basic loss per share from continuing operations of KRW 618.2 a year ago. Basic earnings per share was KRW 13,870.4 compared to basic loss per share of KRW 618.2 a year ago.
Ilsung IS Co Ltd, formerly Ilsung Pharmaceutical Co Ltd, is a Korea-based company mainly engaged in the pharmaceuticals manufacture and sale business. The Companyâs products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The Company distributes its products through wholesalers, hospitals, pharmacies and others. The Company also provides consignment production services.
ILSUNG IS CO., LTD. 
